IMTX
IMTX clinical trials: Immatics N.V.
Every trial on ClinicalTrials.gov where Immatics N.V. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 18
- Trials linked
- 14
- As lead sponsor
- 4
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
IMTX on the catalyst calendar · IMTX registry changes
- Primary completion Jan 2028Sponsor estimatePhase 3NCT06743126SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous MelanomaImmatics US, Inc. · Melanoma, Cutaneous MalignantRecruitingIMTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2027Sponsor estimatePhase 1/Phase 2NCT05958121IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid TumorsImmatics Biotechnologies GmbH · Refractory CancerRecruitingIMTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2028Sponsor estimatePhase 1/Phase 2NCT03686124ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid TumorsImmatics US, Inc. · Refractory CancerRecruitingIMTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 18, 2026ActualPhase 1NCT05359445IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint InhibitorImmatics Biotechnologies GmbH · Refractory CancerActive, not recruitingIMTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2029Sponsor estimatePhase 1NCT06946225ACTengine® IMA203 Combined With mRNA-4203Immatics US, Inc. · Cutaneous MelanomaRecruitingIMTXLeadMRNACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 15, 2022ActualNo phase registeredNCT03760952Human Leukocyte Antigen Typing and Tumor Antigen Expression ProfilingImmatics US, Inc. · Refractory CancerCompletedIMTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 17, 2022ActualPhase 1NCT03441100TCR-engineered T Cells in Solid Tumors: IMA202-101Immatics US, Inc. · Solid Tumor, AdultCompletedIMTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 20, 2023ActualPhase 1NCT03247309TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101)Immatics US, Inc. · Solid TumorCompletedIMTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 22, 2021ActualPhase 1NCT02876510ACTolog in Patients With Solid CancersImmatics US, Inc. · CancerCompletedIMTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2018ActualPhase 1NCT02149225GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma PatientsImmatics Biotechnologies GmbH · GlioblastomaCompletedIMTXLeadBNTXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2015ActualPhase 3NCT01265901IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell CarcinomaImmatics Biotechnologies GmbH · Metastatic Renal Cell CarcinomaCompletedIMTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2014ActualPhase 1NCT01403285Peptide-based Glioma Vaccine IMA950 in Patients With GlioblastomaImmatics Biotechnologies GmbH · GlioblastomaTerminatedIMTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2011ActualPhase 1/Phase 2NCT00785122IMA910 Plus GM-CSF With Low-dose Cyclophosphamide Pre-treatment in Advanced Colorectal Carcinoma Patients Following a Successful 12 Week...Immatics Biotechnologies GmbH · Colorectal CarcinomaCompletedIMTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2009ActualPhase 2NCT00523159IMA901 in Advanced Renal Cell Carcinoma Patients With Measurable DiseaseImmatics Biotechnologies GmbH · Renal Cell CarcinomaCompletedIMTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 20, 2019ActualPhase 1/Phase 2NCT03203005IMA970A Plus CV8102 in Very Early, Early and Intermediate Stage Hepatocellular Carcinoma PatientsNational Cancer Institute, Naples · Hepatocellular CarcinomaCompletedIMTXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2016ActualPhase 2NCT02054884F16IL2 Plus Paclitaxel in Metastatic Merkel Cell CarcinomaPhilogen S.p.A. · Merkel Cell CarcinomaTerminatedIMTXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2016ActualPhase 1/Phase 2NCT01920191Phase I/II Trial of IMA950 Multi-peptide Vaccine Plus Poly-ICLC in GlioblastomaUniversity Hospital, Geneva · CNS Tumor, AdultCompletedIMTXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2015ActualPhase 1NCT01222221Vaccine Therapy, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCancer Research UK · Brain and Central Nervous System TumorsCompletedIMTXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 18 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner